Eli Lilly Forecasts 21% Revenue, 40% Earnings Growth and $3.5B Plant
Consensus estimates foresee Eli Lilly delivering over 21% revenue growth and more than 40% adjusted earnings growth in 2026 versus 2025. The company plans to invest $3.5 billion in a Pennsylvania pharmaceutical manufacturing plant for injectable weight-loss drugs, with construction starting this year and operations in 2031.
1. Analyst Projections
Consensus estimates expect Eli Lilly to deliver more than 21% revenue growth and over 40% adjusted earnings growth in 2026 compared with 2025, driven by strong demand for its diabetes and obesity therapy franchises.
2. Obesity Market Outlook
Global obesity drug market forecasts have been trimmed to reach around $100 billion by 2030, down from prior $150 billion estimates, with peak potential now seen at roughly $80 billion by 2035 due to pricing pressure and accelerating generic competition.
3. Pennsylvania Manufacturing Investment
On January 30, the company announced a $3.5 billion pharmaceutical manufacturing facility in Pennsylvania, its fourth U.S. site, aimed at producing injectable weight-loss drugs such as retatrutide, with construction beginning this year and full operations slated for 2031.